Back to search

National and Kapodistrian University of Athens

Επίδραση της φαρμακευτικής αγωγής στη λιπώδη νόσο του ήπατος ασθενών με σακχαρώδη διαβήτη τύπου 2, με έμφαση στις νεότερες αντιδιαβητικές θεραπείες

Abstract

dc:description

Introduction: Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common cause of liver disease worldwide. Over time, the therapeutic approach of patients includes a combination of dietary interventions and exercise, aiming at weight loss, with bariatric surgery being the final solution in cases where the initial approach is insufficient. Given the limited available drug options, medical interest has encompassed drugs used for treating the comorbidities of patients with NAFLD. Aim: Aim of the present prospective observational study was to evaluate the effect of Dulaglutide and Empagliflozin on hepatic steatosis, as well as other factors such as body weight, waist circumference, glycemic control, etc. and to compare the results of treatment with these two drugs. Methods: Seventy-eight patients with type 2 Diabetes Mellitus and NAFLD were included in the study, of which 25 belonged to the Empagliflozin group, 25 to the Dulaglutide group and 28 to the control group. Patient evaluation included recording of demographic and anthropometric characteristics, measurement of laboratory parameters and calculation of corresponding scores and indexes related to hepatic steatosis and fibrosis. It also included ultrasonographic and magnetic resonance imaging, at the time of inclusion and at 52 weeks of follow-up, aiming at the assessment of liver stiffness and steatosis. Results: Quantitative assessment of hepatic steatosis by MRI showed that, after one year of treatment, the Empagliflozin group exhibited a statistically significant reduction of liver fat fraction (LFF) from (mean ± SEM) 12.31% ± 1.76% to 9.34% ± 1.39%, (P = 0.007). In contrast, no statistically significant change was observed in the Dulaglutide group and the control group. Additionally, 52% of patients in the Empagliflozin group achieved a relative reduction of LFF of at least 30%. Furthermore, significant reductions in Body Mass Index (BMI) and Fatty Liver Index (FLI) were recorded in all 3 groups, with the Empagliflozin and Dulaglutide groups appearing superior to the control group, as far as weight loss achievement of at least 5% was concerned. Finally, significant positive correlations were observed between changes in LFF and BMI, HbA1c, FLI, aminotransferase levels, AST to Platelet Ratio Index (APRI) and both waist and hip circumference. Conclusions: In the present study, treatment with Empagliflozin appeared to be superior, regarding improvement of hepatic steatosis, compared to the treatment with Dulaglutide, which, despite improving BMI, did not significantly reduce LFF.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Koullias, Emmanouil
  • Κουλλιάς, Εμμανουήλ

Subjects

dc:subject × 21

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/58443

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Koullias, Emmanouil; Κουλλιάς, Εμμανουήλ. Επίδραση της φαρμακευτικής αγωγής στη λιπώδη νόσο του ήπατος ασθενών με σακχαρώδη διαβήτη τύπου 2, με έμφαση στις νεότερες αντιδιαβητικές θεραπείες. National and Kapodistrian University of Athens, 2025. http://hdl.handle.net/10442/hedi/58443